Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(16 sites)
United Kingdom
Brighton and Sussex University Hospital, Brighton, Default Velindre Cancer Centre, Cardiff, Default Edinburgh Cancer Centre (NHS Lothian), Edinburgh, Default Royal Surrey NHS Foundation, Guildford, Default Imperial College Healthcare NHS Trust, London, Default Mount Vernon, London, Default University College London Hospital NHS Foundation Trust, London, Default Christie NHS Foundation Trust, Manchester, Default Nottingham University Hospitals Cancer Centre, Nottingham, Default Lancashire Teaching Hospitals NHS Foundation Trust, Preston, Default Sheffield Teaching Hospital NHS Foundation Trust, Sheffield, Default The Royal Marsden NHS Foundation Trust, Sutton, Default Belfast City Hospital, Belfast Addenbrooke's Hospital, Cambridge University Hospitals, Cambridge The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool Torbay and South Devon NHS Foundation Trust, Torquay